A Longitudinal Study of Brain Volume Changes in Children With Growth Hormone Deficiency Treated With Recombinant Human Growth Hormone

The human brain is not a static organ; it is a living structure that grows, reshapes, and refines itself throughout childhood. This development relies on a complex network of chemical signals, one of the most important being growth hormone. Produced by a tiny gland at the base of the brain called the pituitary, this hormone acts as a master regulator, directing not only how tall a child grows but also how their body uses energy and how their bones strengthen. For decades, doctors have known that when children lack this hormone, they fail to reach their expected height. What has remained less clear is whether this deficiency leaves a mark on the brain itself, and if treating the body with synthetic growth hormone can help the brain recover its normal shape and size.

A team of researchers in Malaysia set out to answer these questions by looking directly inside the brains of children with a specific condition known as isolated growth hormone deficiency. This means the children had a shortage of growth hormone but were otherwise healthy, with no other hormonal problems or genetic syndromes. The researchers wanted to see if the lack of this vital hormone changed the physical volume of different brain parts and, crucially, whether giving the children the missing hormone could reverse those changes. By using detailed magnetic resonance imaging, or MRI, to take precise measurements of brain structures before and after treatment, the study offers a rare glimpse into how the brain responds to hormonal therapy over time.

The study followed forty-three children who had been diagnosed with this hormone deficiency. Before they began treatment, the children underwent an MRI scan. The researchers then started them on a course of synthetic human growth hormone, a standard therapy that helps children grow taller. After an average of one and a half years of treatment, the children returned for a second MRI scan. To understand what was normal, the team compared these scans to those of healthy children of similar ages and genders, creating two separate groups of healthy peers to match the children at the start and at the end of the study period. The researchers used advanced computer software to measure the size of the pituitary gland itself, as well as several key areas deep within the brain, including the thalamus, the hippocampus, and the corpus callosum, a thick bundle of nerve fibers that connects the left and right sides of the brain.

The results revealed that the brain of a child with untreated growth hormone deficiency is physically different from that of a healthy child, but not in a single, uniform way. At the start of the study, the pituitary glands of the children with the deficiency were significantly smaller than those of their healthy peers. This was expected, as the gland is the source of the missing hormone. However, the researchers also found that a specific part of the brain's connecting bridge, called the splenium, was also smaller. In a surprising twist, other parts of that same connecting bridge, as well as the thalamus, were actually larger in the children with the deficiency. This suggests that the lack of growth hormone does not simply shrink the brain; it disrupts the normal pattern of growth, causing some areas to lag behind while others expand abnormally.

When the children returned for their second scan after receiving treatment, the changes were distinct and measurable. The pituitary glands showed a strong response, growing significantly larger and moving closer to the size seen in healthy children, though they did not fully catch up. The splenium, the part that had been too small, also grew, showing signs of recovery. Conversely, the areas that had been abnormally large at the start, such as the front and middle sections of the connecting bridge, actually shrank back toward normal sizes. The thalamus and other deep brain structures continued to grow, following a trajectory that aligned more closely with healthy development. These findings indicate that the treatment does not just stop the deficiency; it actively guides the brain back toward a healthier structural path, correcting some of the irregularities caused by the lack of hormones.

The study suggests that the brain is highly sensitive to the levels of growth hormone circulating in the body. The fact that some brain regions grew while others shrank in response to the same treatment highlights that different parts of the brain react in unique ways. The researchers noted that while the treatment helped normalize the size of many structures, the brain did not instantly return to a perfect state. The pituitary gland, for instance, remained slightly smaller than average even after treatment, suggesting that early disruption in hormone levels can leave a lasting mark that therapy can improve but not completely erase. This partial recovery is a significant finding, as it shows that the brain retains a degree of plasticity and can adapt even after a period of deficiency.

Importantly, the study did not find that every part of the brain was affected. Structures like the hippocampus, which is involved in memory, and the amygdala, which processes emotions, did not show significant size differences between the children with the deficiency and the healthy children at the start. This tells us that the impact of growth hormone deficiency is selective, affecting specific pathways while leaving others relatively untouched. The treatment appeared to support the natural growth of these unaffected areas, allowing them to develop at a pace similar to their healthy peers.

This research provides a new way to look at the effects of growth hormone deficiency. For years, doctors have monitored the success of treatment by measuring how fast a child grows in height. This study adds a new dimension by showing that the brain itself is a target of the treatment. The ability to see these structural changes on an MRI scan offers a more complete picture of what is happening inside the body. It confirms that the brain is not just a passive observer of growth but an active participant that responds to the availability of growth hormone. While the study does not yet link these physical changes to how the children think or behave, it lays the groundwork for future research to explore whether these structural improvements translate into better cognitive outcomes.

The findings also highlight the potential of using brain scans as a tool to monitor treatment. By measuring the volume of specific brain regions, doctors might one day be able to assess how well a child is responding to therapy beyond just their height. This could be particularly useful for understanding the long-term effects of the deficiency and ensuring that the brain is developing as healthily as possible. The study concludes that while growth hormone deficiency creates a unique pattern of brain changes, the introduction of synthetic growth hormone can help correct many of these abnormalities, guiding the brain back toward a more typical developmental path.